Clinical trial
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With…
NCT00088101 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00088101 |
|---|---|
| Title | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors |
| Official title | Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors |
| Intervention type | Drug |
| Interventions | STA-5312 |
| Enrollment | 42 |
| Start date | Feb 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jul 21, 2004 |
| Last update posted | Dec 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: